Literature DB >> 12018818

The value of MG7 antigen in predicting cancerous change in dysplastic gastric mucosa.

J Liu1, J L Hu, X Y Zhang, T D Qiao, X T Chen, K C Wu, J Ding, D M Fan.   

Abstract

The aim of this study was to ascertain whether MG7Ag is a useful predictor of evolution of gastric dysplasia to carcinoma. A total of 1090 patients with confirmed dysplasia were stained immunohistochemically with MG7 monoclonal antibody by the ABC method. A prospective follow-up study was undertaken on 19 patients with MG7Ag positive staining and 16 with MG7 negative staining over a period of 10-78 months. The expression of MG7Ag was also compared in another two groups by conducting retrospective studies. One group showed an evolution into gastric cancer over 2-4 years, the other did not. Quantitative analysis of MG7Ag expression was carried out on the last two groups. The receiver operating characteristic curve and Youden index were used to assess the best critical value for MG7Ag. MG7Ag was found positive in 456/1090 cases (41.8%) with dysplasia. Prospective follow-up of 35 patients showed that 6/19 patients with MG7Ag positive staining developed gastric cancer, but there were no carcinomatous changes in 16 patients with MG7 negative staining. The results of MG7Ag expression in 72 cases with retrospective follow-up showed there were 24 with positive immunostaining among 34 cancerous cases (70.6%), and only 7 in 38 non-cancerous cases (18.4%) (p<0.01). Image analysis showed that an average MG7Ag density index ++0.19 could be regarded as the critical value for high risk of gastric mucosa with dysplasia evolving to cancer. Positive MG7Ag expression in gastric mucosa of patients with dysplasia, especially in cases with a density index ++0.19, was an indicator of high risk of malignant change.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018818

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

1.  Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.

Authors:  T Lin; S Liang; F Meng; Q Han; C Guo; L Sun; Y Chen; Z Liu; Z Yu; H Xie; J Ding; D Fan
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.

Authors:  Xiao-Dong Wang; Ning-Ning Gao; Yu-Wen Diao; Yu Liu; Dong Gao; Wang Li; Yan-Yan Wan; Jing-Jing Zhong; Guang-Yi Jin
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

3.  Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer.

Authors:  Fan-Ping Meng; Jie Ding; Zhao-Cai Yu; Quan-Li Han; Chang-Cun Guo; Na Liu; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

4.  Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier.

Authors:  Chang-Cun Guo; Jie Ding; Bo-Rong Pan; Zhao-Cai Yu; Quan-Li Han; Fan-Ping Meng; Na Liu; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer.

Authors:  Bing Xu; Xiaowei Li; Jipeng Yin; Cong Liang; Lijuan Liu; Zhaoyan Qiu; Liping Yao; Yongzhan Nie; Jing Wang; Kaichun Wu
Journal:  Sci Rep       Date:  2015-03-03       Impact factor: 4.379

6.  Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.

Authors:  Xiaodong Wang; Yu Liu; Yuwen Diao; Ningning Gao; Yanyan Wan; Jingjing Zhong; Huali Zheng; Zhulin Wang; Guangyi Jin
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.